Efficacy and safety of denosmab in patients with glucocorticoid-induced osteoporosis refractory to combination therapy with bisphosphonate and vitamin D
Not Applicable
- Conditions
- Glucocorticoid-induced osteoporosis
- Registration Number
- JPRN-UMIN000020711
- Lead Sponsor
- Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Persons who had allergy to ingredients of denosmab injection, hypocalcemia, plan for invasive dental therapy, such as dental extraction, previous or current use of denosmab or teriparatide, and renal dysfunction with estimated glomerular filtration rate below 30% were excluded. Pregnant and breastfeeding women, woman who have plan for pregnancy, and persons judged as ineligible for this study by attending physician were also excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method